6kn9: Difference between revisions

Line 1:

~~'''Unreleased structure'''~~

~~The entry~~ 6kn9 is ~~ON HOLD until Paper~~ Publication

==Crystal structure of human interleukin 18 receptor beta extracellular domain in complex with an antagonistic scFv==

== Structural highlights ==

<table><tr><td colspan='2'>[[6kn9]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KN9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6KN9 FirstGlance]. <br>

</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>

<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6kn9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6kn9 OCA], [http://pdbe.org/6kn9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6kn9 RCSB], [http://www.ebi.ac.uk/pdbsum/6kn9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6kn9 ProSAT]</span></td></tr>

</table>

== Publication Abstract from PubMed ==

The interleukin-18 subfamily belongs to the interleukin-1 family and plays an important role in modulating innate and adaptive immune responses. Dysregulation of IL-18 has been implicated in or correlated with numerous diseases, including inflammatory diseases, autoimmune disorders, and cancer. Thus, blockade of IL-18 signaling may offer therapeutic benefits in many pathological settings. Here, we report the development of synthetic human antibodies that target human IL-18Rbeta and block IL-18-mediated IFN-gamma secretion by inhibiting NF-kappaB and MAPK dependent pathways. The crystal structure of a potent antagonist antibody in complex with IL-18Rbeta revealed inhibition through an unexpected allosteric mechanism. Our findings offer a novel means for therapeutic intervention in the IL-18 pathway and may provide a new strategy for targeting cytokine receptors.

~~Authors~~:

A Synthetic Human Antibody Antagonizes IL-18Rbeta Signaling Through an Allosteric Mechanism.,Liu S, Miersch S, Li P, Bai B, Liu C, Qin W, Su J, Huang H, Pan J, Sidhu SS, Wu D J Mol Biol. 2020 Jan 15. pii: S0022-2836(20)30042-5. doi:, 10.1016/j.jmb.2020.01.012. PMID:31954129<ref>PMID:31954129</ref>

~~Description~~:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>

[[Category: ~~Unreleased~~ Structures]]

</div>

== References ==

__TOC__

</StructureSection>

[[Category: Large Structures]]

[[Category: Liu, C C]]

[[Category: Wu, D H]]

[[Category: Antagonist]]

[[Category: Antibody]]

[[Category: Complex]]

[[Category: Cytokine]]

[[Category: Interleukin receptor]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 6kn9 is ON HOLD  until Paper Publication
+==Crystal structure of human interleukin 18 receptor beta extracellular domain in complex with an antagonistic scFv==
+<StructureSection load='6kn9' size='340' side='right'caption='[[6kn9]], [[Resolution|resolution]] 3.30&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[6kn9]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KN9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6KN9 FirstGlance]. <br>
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6kn9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6kn9 OCA], [http://pdbe.org/6kn9 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6kn9 RCSB], [http://www.ebi.ac.uk/pdbsum/6kn9 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6kn9 ProSAT]</span></td></tr>
+</table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+The interleukin-18 subfamily belongs to the interleukin-1 family and plays an important role in modulating innate and adaptive immune responses. Dysregulation of IL-18 has been implicated in or correlated with numerous diseases, including inflammatory diseases, autoimmune disorders, and cancer. Thus, blockade of IL-18 signaling may offer therapeutic benefits in many pathological settings. Here, we report the development of synthetic human antibodies that target human IL-18Rbeta and block IL-18-mediated IFN-gamma secretion by inhibiting NF-kappaB and MAPK dependent pathways. The crystal structure of a potent antagonist antibody in complex with IL-18Rbeta revealed inhibition through an unexpected allosteric mechanism. Our findings offer a novel means for therapeutic intervention in the IL-18 pathway and may provide a new strategy for targeting cytokine receptors.
-Authors:
+A Synthetic Human Antibody Antagonizes IL-18Rbeta Signaling Through an Allosteric Mechanism.,Liu S, Miersch S, Li P, Bai B, Liu C, Qin W, Su J, Huang H, Pan J, Sidhu SS, Wu D J Mol Biol. 2020 Jan 15. pii: S0022-2836(20)30042-5. doi:, 10.1016/j.jmb.2020.01.012. PMID:31954129<ref>PMID:31954129</ref>
-Description:
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-[[Category: Unreleased Structures]]
+</div>
+<div class="pdbe-citations 6kn9" style="background-color:#fffaf0;"></div>
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Large Structures]]
+[[Category: Liu, C C]]
+[[Category: Wu, D H]]
+[[Category: Antagonist]]
+[[Category: Antibody]]
+[[Category: Complex]]
+[[Category: Cytokine]]
+[[Category: Interleukin receptor]]